Kui K Chan1, Timothy J C Tan2, Krishna K Narayanan2, Erik Procko3. 1. Orthogonal Biologics, Champaign, IL 61821, USA. 2. Department of Biochemistry and Cancer Center at Illinois, University of Illinois, Urbana, IL 61801, USA. 3. Department of Biochemistry and Cancer Center at Illinois, University of Illinois, Urbana, IL 61801, USA. procko@illinois.edu.
Abstract
The spike S of SARS-CoV-2 recognizes ACE2 on the host cell membrane to initiate entry. Soluble decoy receptors, in which the ACE2 ectodomain is engineered to block S with high affinity, potently neutralize infection and, because of close similarity with the natural receptor, hold out the promise of being broadly active against virus variants without opportunity for escape. Here, we directly test this hypothesis. We find that an engineered decoy receptor, sACE22v2.4, tightly binds S of SARS-associated viruses from humans and bats, despite the ACE2-binding surface being a region of high diversity. Saturation mutagenesis of the receptor-binding domain followed by in vitro selection, with wild-type ACE2 and the engineered decoy competing for binding sites, failed to find S mutants that discriminate in favor of the wild-type receptor. We conclude that resistance to engineered decoys will be rare and that decoys may be active against future outbreaks of SARS-associated betacoronaviruses.
The spike S of SARS-CoV-2 recognizes ACE2 on the host cell membrane to initiate entry. Soluble decoy receptors, in which the ACE2 ectodomain is engineered to block S with high affinity, potently neutralize infection and, because of close similarity with the natural receptor, hold out the promise of being broadly active against virus variants without opportunity for escape. Here, we directly test this hypothesis. We find that an engineered decoy receptor, sACE22v2.4, tightly binds S of SARS-associated viruses from humans and bats, despite the ACE2-binding surface being a region of high diversity. Saturation mutagenesis of the receptor-binding domain followed by in vitro selection, with wild-type ACE2 and the engineered decoy competing for binding sites, failed to find S mutants that discriminate in favor of the wild-type receptor. We conclude that resistance to engineered decoys will be rare and that decoys may be active against future outbreaks of SARS-associated betacoronaviruses.
Authors: Yaozong Chen; Lulu Sun; Irfan Ullah; Guillaume Beaudoin-Bussières; Sai Priya Anand; Andrew P Hederman; William D Tolbert; Rebekah Sherburn; Dung N Nguyen; Lorie Marchitto; Shilei Ding; Di Wu; Yuhong Luo; Suneetha Gottumukkala; Sean Moran; Priti Kumar; Grzegorz Piszczek; Walther Mothes; Margaret E Ackerman; Andrés Finzi; Pradeep D Uchil; Frank J Gonzalez; Marzena Pazgier Journal: Sci Adv Date: 2022-07-13 Impact factor: 14.957
Authors: Leonidas Stamatatos; Julie Czartoski; Yu-Hsin Wan; Leah J Homad; Vanessa Rubin; Hayley Glantz; Moni Neradilek; Emilie Seydoux; Madeleine F Jennewein; Anna J MacCamy; Junli Feng; Gregory Mize; Stephen C De Rosa; Andrés Finzi; Maria P Lemos; Kristen W Cohen; Zoe Moodie; M Juliana McElrath; Andrew T McGuire Journal: medRxiv Date: 2021-03-10
Authors: Matthew D Hall; James M Anderson; Annaliesa Anderson; David Baker; Jay Bradner; Kyle R Brimacombe; Elizabeth A Campbell; Kizzmekia S Corbett; Kara Carter; Sara Cherry; Lillian Chiang; Tomas Cihlar; Emmie de Wit; Mark Denison; Matthew Disney; Courtney V Fletcher; Stephanie L Ford-Scheimer; Matthias Götte; Abigail C Grossman; Frederick G Hayden; Daria J Hazuda; Charlotte A Lanteri; Hilary Marston; Andrew D Mesecar; Stephanie Moore; Jennifer O Nwankwo; Jules O'Rear; George Painter; Kumar Singh Saikatendu; Celia A Schiffer; Timothy P Sheahan; Pei-Yong Shi; Hugh D Smyth; Michael J Sofia; Marla Weetall; Sandra K Weller; Richard Whitley; Anthony S Fauci; Christopher P Austin; Francis S Collins; Anthony J Conley; Mindy I Davis Journal: J Infect Dis Date: 2021-07-15 Impact factor: 7.759